Skip to main content

Experimental Onco-Immunology Revisited

Buy Article:

$55.00 plus tax (Refund Policy)

The search for the cause of cancer has led to five successive theories involving viruses, oncogenes, tumor suppressor genes, somatic mutation cascade and inflammation. The latter, without discarding the former theories, is now the prevailing paradigm recognizing that neoplastic cells require participation of the microenvironment for tumor progression. Inflammatory reactions are dependent on an overabundance of immune responses which are both in favor and against tumor development. This homeostatic immunological behavior has led to the concept of tumor immunoediting in an attempt to elucidate why tumors grow. This review is a non-exhaustive description of the different experimental highlights which have led to our present knowledge of cancer. During its 47 years of existence, our laboratory has contributed extensively to the experimental development of onco-immunology, so that our results are described within the background of international discoveries. As for cancer therapy, the many attempts made, both at the experimental and clinical levels, have been mainly frustrating and yet, as oncologists, we are always ready to try again.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: anti-oncogene; experimental oncology; mmtv; oncogene; retrovirus; tumor immunoediting

Document Type: Review Article

Affiliations: Division Medicina Experimental (ILEX-CONICET), Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, 1425 Buenos Aires, Argentina.

Publication date: 2005-11-01

More about this publication?
  • Current Cancer Therapy Reviews publishes frontier reviews on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more